Canada’s Colorectal Cancer Therapeutics market size stood at around USD XX billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of X.X% during the forecast period.
Canada’s Colorectal Cancer therapeutics market is expected to grow significantly over the forecast period. Colorectal cancer is the 3rd most common cancer in Canada with 93% of cases occurring in adults aged 50+. An estimated 26,900 Canadians have been diagnosed with colorectal cancer in 2019. . On average, every day 73 Canadians will be diagnosed with colorectal cancer, and 27 Canadians will die from it. Diet, tobacco smoking and heavy alcohol use, people with certain hereditary cancer syndromes or a family history of colorectal cancer have a high risk of developing the disease.
Market Driving Factors
The driving factors for the growth of the colorectal cancer therapeutics market in Canada include rising prevalence, overweight or obesity, a diet high in processed meat or red meat, Persistent investment in R&D, greater adoption of sophisticated and advanced therapies. It is the 2nd leading cause of death from cancer in men and the 3rd leading cause of death from cancer in women in Canada. Serious impacts of colorectal cancer on human health leading to metastasis of cancer will propel growth. Also, the launch of several novel therapeutics for a cancer cure and the rise in awareness about the presence of effective therapeutics is further expected to help increase the overall colorectal cancer therapeutics market size in the forecast period.